Biogen Idec Enrolls First Patient In BG-12 Combination Phase II Trial
The trial, called Explore, is expected to evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNß) or glatiramer acetate (GA) to patients who continue
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.